Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Charles Wiseman

Charles Wiseman

Briacell Therapeutics, USA

Title: Targeted Immunotherapy for Breast Cancer Immunotherapy - Fact, myths and experience: Mythbusters: How beautiful facts can falsify ugly theories

Biography

Biography: Charles Wiseman

Abstract

In the 70’s, there was great excitement about the promise of BCG to as a new approach to treating many cancers, breast cancer included. That idea didn’t prove true, as did many widely held concepts. We have come a long way in the past 50 years, and it should be helpful to pay some attention to the developments that led us to the current state. The recent positive results with the SV-BR1-GM targeted therapy stand in contrast to some of the previous ‘widely held concepts’; During the discussion, I will discuss objective findings that refute the following:

Breast cancer is not immunogenic

Targeted Immunotherapy is effective only if <10^6 cells

BCG can aid tumor regression and extend survival

Chemotherapy is immunosuppressive and would neutralize any immunotherapy benefit

The brain is a privileged site,

Responses to immunotherapy are very slow

Considering some of the past perspectives, with my discussion of the positive results of my own work and that of others, I will offer a few speculations and discuss some unsolved challenges to developing an effective therapy for breast cancer.